Cargando…
Metallodrugs against Breast Cancer: Combining the Tamoxifen Vector with Platinum(II) and Palladium(II) Complexes
The luminal A-subtype of breast cancer, where the oestrogen receptor α (ERα) is overexpressed, is the most frequent one. The prodrug tamoxifen (1) is the clinically used agent, inhibiting the ERα activity via the formation of several active metabolites, such as 4-hydroxytamoxifen (2) or 4,4′-dihydro...
Autores principales: | Kazimir, Aleksandr, Schwarze, Benedikt, Lönnecke, Peter, Jelača, Sanja, Mijatović, Sanja, Maksimović-Ivanić, Danijela, Hey-Hawkins, Evamarie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959148/ https://www.ncbi.nlm.nih.gov/pubmed/36840003 http://dx.doi.org/10.3390/pharmaceutics15020682 |
Ejemplares similares
-
Correction: Kazimir et al. Metallodrugs against Breast Cancer: Combining the Tamoxifen Vector with Platinum(II) and Palladium(II) Complexes. Pharmaceutics 2023, 15, 682
por: Kazimir, Aleksandr, et al.
Publicado: (2023) -
2,2′‐Bipyridine‐Modified Tamoxifen: A Versatile Vector for Molybdacarboranes
por: Schwarze, Benedikt, et al.
Publicado: (2019) -
Synthesis and In Vitro Biological Evaluation of p-Carborane-Based Di-tert-butylphenol Analogs
por: Braun, Sebastian, et al.
Publicado: (2023) -
Ruthenacarborane–Phenanthroline Derivatives as Potential Metallodrugs
por: Kellert, Martin, et al.
Publicado: (2020) -
Ruthenacarborane and Quinoline: A Promising Combination for the Treatment of Brain Tumors
por: Drača, Dijana, et al.
Publicado: (2021)